Septerna (NASDAQ:SEPN) Now Covered by Cantor Fitzgerald

Research analysts at Cantor Fitzgerald started coverage on shares of Septerna (NASDAQ:SEPN) in a report issued on Tuesday,Briefing.com Automated Import reports. The firm set an “overweight” rating and a $50.00 price target on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 112.31% from the company’s current price.

Separately, TD Cowen initiated coverage on Septerna in a research report on Tuesday. They set a “buy” rating for the company.

Septerna Stock Up 4.5 %

SEPN opened at $23.55 on Tuesday. Septerna has a one year low of $18.62 and a one year high of $26.34.

Insider Activity

In other news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $6,669,000.00. Following the transaction, the insider now directly owns 6,215,591 shares of the company’s stock, valued at approximately $111,880,638. This trade represents a 6.34 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.